Skip to main content
Terug
Watch Compare

Altimmune, Inc.

Datakwaliteit: 100%
ALT
Nasdaq Manufacturing Chemicals
€ 3,36
▼ € 0,02 (-0,45%)
Marktkapitalisatie: 436,50 M
Prijs
€ 3,36
Marktkapitalisatie
436,50 M
Dagbereik
€ 3,31 — € 3,38
52-Weeksbereik
€ 2,87 — € 7,73
Volume
965.594
Openen € 3,37
50D / 200D Gem.
€ 4,20
20,11% below
50D / 200D Gem.
€ 4,21
20,27% below

Quick Summary

Belangrijkste Punten

Revenue declined -68,95% annually over 5 years
Debt/Equity of 0,08 — conservative balance sheet
Negative free cash flow of -67,55 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 173,95%

Groei

Revenue Growth (5Y)
-68,95%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)105,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-50,78%
Boven sectorgemiddelde (-53,41%)
ROIC-38,58%
Net Margin-214860,98%
Op. Margin-230460,98%

Veiligheid

Debt / Equity
0,08
Onder sectorgemiddelde (0,31)
Current Ratio17,18
Interest Coverage-57,76

Waardering

PE (TTM)
-4,96
Onder sectorgemiddelde (-1,48)
P/B Ratio2,35
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -5,0 -1,5
P/B 2,4 1,6
ROE % -50,8 -53,4
Net Margin % -214861,0 -41,5
Rev Growth 5Y % -69,0 1,8
D/E 0,1 0,3

ETFs Holding This Stock

BBC logo BBC Virtus Biotech Clinical Trials ETF
0,41% weight
FSCC logo FSCC Federated Hermes MDT Small Cap Core ETF
0,27% weight
DLHIX DLHIX
0,05% weight
DLHAX DLHAX
0,05% weight
DLRHX DLRHX
0,05% weight
AVSU logo AVSU Avantis Responsible U.S. Equity ETF
0,00% weight
IWV logo IWV iShares Russell 3000 ETF
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 105,00% Revenue Growth (3Y) -68,98%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -68,95% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 41.000,0 Net Income (TTM) -88,09 M
ROE -50,78% ROA -43,10%
Gross Margin N/A Operating Margin -230460,98%
Net Margin -214860,98% Free Cash Flow (TTM) -67,55 M
ROIC -38,58% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,08 Current Ratio 17,18
Interest Coverage -57,76 Asset Turnover 0,00
Working Capital 204,01 M Tangible Book Value 185,60 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -4,96 Forward P/E N/A
P/B Ratio 2,35 P/S Ratio 10646,41
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -15,47%
Market Cap 436,50 M Enterprise Value 389,71 M
Per Share
EPS (Diluted TTM) -1,00 Revenue / Share 0,00
FCF / Share -0,52 OCF / Share -0,52
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 26,83% FCF Conversion 76,68%
SBC-Adj. FCF -81,76 M Growth Momentum 173,95

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 41.000,0 20.000,0 426.000,0 -68.000,0 4,41 M
Net Income -88,09 M -95,06 M -88,45 M -84,71 M -97,09 M
EPS (Diluted) -1,00 -1,34 -1,66 -1,81 -2,35
Gross Profit — — — — —
Operating Income -94,49 M -103,17 M -95,93 M -87,74 M -96,91 M
EBITDA — — — — —
R&D Expenses 66,43 M 82,23 M 65,80 M 70,54 M 74,54 M
SG&A Expenses — — — — —
D&A — — — — 551.301,0
Interest Expense 1,64 M 9.000,0 35.000,0 8.000,0 5.656,0
Income Tax -681.000,0 — -197.000,0 -197.000,0 -5,42 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 279,93 M 139,31 M 210,64 M 206,93 M 218,86 M
Total Liabilities 55,04 M 15,80 M 16,54 M 21,64 M 19,73 M
Shareholders' Equity 224,89 M 123,51 M 194,10 M 185,29 M 199,13 M
Total Debt 34,29 M — — 4,58 M 1,45 M
Cash & Equivalents 43,76 M 36,93 M 135,12 M 111,10 M 190,30 M
Current Assets 278,19 M 137,25 M 209,63 M 192,81 M 204,13 M
Current Liabilities 15,00 M 10,47 M 12,14 M 17,05 M 18,28 M